Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

Figure 3

Spearman’s correlation analysis of AUC with toxicity and tumor shrinkage induced by lenvatinib. The worst grade of hypertension (A), proteinuria (B), and fatigue (C) and the maximum tumor shrinkage (D) for the treatment duration were analyzed in correlation with AUC0-tau. The correlation coefficient (r) and P value for each analysis is indicated.

Back to article page